Allogene Therapeutics
Joshua is a Co-Founder and Director of Allogene Therapeutics. Joshua Kazam is a Co-Founder and Partner of Two River, where he has served as Partner since its inception in 2004. He is a Co-Founder and Partner of Vida Ventures, LLC, a life science investment firm, and was a Co-Founder and Director of Kite Pharma, where he served on the Board of Directors from inception until its acquisition by Gilead Sciences in 2017. Joshua also serves as a Director of several privately held companies including Kronos Bio, Hubble Contacts, ByHeart Inc, and Breakthrough Properties, LLC. Joshua is a Member of the Wharton School’s Undergraduate Executive Board and serves on the Board of the Desert Flower Foundation. He received his B.S. in Economics from the Wharton School of the University of Pennsylvania.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.